BioSpace News Archive

Business

TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018

TESARO, Inc. will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets.

October 25, 2018
·
1 min read
Business

Oxurion NV Business Update – Q3 2018

Shareholders’ Approval and Launch of Oxurion NV as new Company Name

October 25, 2018
·
10 min read
Business

Orbita takes steps to drive innovation in conversational AI and voice technology solutions for health care

Voice solution provider now working with academic medical center to explore opportunities to improve patient care

October 25, 2018
·
3 min read
Policy

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin Neurosciences today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla™ (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.

October 25, 2018
·
6 min read
Drug Development

MorphoSys’s Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference

MorphoSys AG announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). The study was conducted in patients with moderate to severe RA who had an inadequate response to methotrexate.

October 25, 2018
·
4 min read
Drug Development

G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer

New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy

October 25, 2018
·
8 min read
Drug Development

Regeneron and Roche Duke It out in the Diabetic Retinopathy Market

Regeneron Pharmaceuticals’ Eylea (aflibercept) showed strongly positive data in a Phase III trial in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR). The trial met its 52-week primary endpoint and key secondary endpoints.

October 25, 2018
·
2 min read
·
Mark Terry
Drug Development

MIT Researchers Discover CRISPR Enzyme That Can Target Almost Half of Genome Locations

Yesterday, researchers at the Massachusetts Institute of Technology (MIT) published research in the journal Science Advances describing yet another CRISPR improvement.

October 25, 2018
·
2 min read
·
Mark Terry
Drug Development

Polyphor to present new survival data for balixafortide at the 2018 European Society for Medical Oncology (ESMO) Congress

Polyphor announced today that new survival data from clinical and preclinical trials of balixafortide will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23.

October 25, 2018
·
3 min read
Business

Immunicum AB (publ) Announces Nomination Committee for AGM 2019

Immunicum AB (publ) in accordance with the principles of appointing the Nomination Committee, adopted by the Annual General Meeting of April 25, 2018, announced today that the members of the Nomination Committee have been appointed.

October 25, 2018
·
1 min read